9SB Stock Overview
SOL Global Investments Corp. is a private equity firm specializing in growth capital to small and mid-sized businesses.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SOL Global Investments Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.025 |
| 52 Week High | CA$0.20 |
| 52 Week Low | CA$0.015 |
| Beta | 0.87 |
| 1 Month Change | -21.88% |
| 3 Month Change | -54.55% |
| 1 Year Change | -13.79% |
| 3 Year Change | -99.07% |
| 5 Year Change | -98.48% |
| Change since IPO | -98.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 9SB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 16.3% | 2.3% | 0.5% |
| 1Y | -13.8% | -28.6% | 1.3% |
Return vs Industry: 9SB exceeded the German Pharmaceuticals industry which returned -28.2% over the past year.
Return vs Market: 9SB underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 9SB volatility | |
|---|---|
| 9SB Average Weekly Movement | 38.5% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 9SB's share price has been volatile over the past 3 months.
Volatility Over Time: 9SB's weekly volatility has increased from 30% to 39% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Paul Kania | solglobal.com |
SOL Global Investments Corp. is a private equity firm specializing in growth capital to small and mid-sized businesses. The firm primarily invests in U.S cannabis industry, CBD, health and wellness, E-sports, electric mobility sector. SOL Global Investments Corp. is based in Toronto, Canada.
SOL Global Investments Corp. Fundamentals Summary
| 9SB fundamental statistics | |
|---|---|
| Market cap | €1.67m |
| Earnings (TTM) | -€23.29m |
| Revenue (TTM) | n/a |
-0.1x
P/S Ratio-0.1x
P/E RatioIs 9SB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 9SB income statement (TTM) | |
|---|---|
| Revenue | -CA$31.51m |
| Cost of Revenue | CA$0 |
| Gross Profit | -CA$31.51m |
| Other Expenses | CA$2.62m |
| Earnings | -CA$34.13m |
Last Reported Earnings
Nov 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.63 |
| Gross Margin | 100.00% |
| Net Profit Margin | 108.32% |
| Debt/Equity Ratio | 412.9% |
How did 9SB perform over the long term?
See historical performance and comparison